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Adenosine antagonist theophylline prevents the reduction of glomerular
filtration rate after contrast media application. Radiographic contrast
media (CM) can induce renal failure and this may serve as an experi-
mental model of acute renal failure (ARF). One vasoactive factor likely
to be involved in ARF is adenosine. In a double-blind, placebo-
controlled study we investigated the effect of theophylline (TP), an
adenosine receptor antagonist, regarding changes in renal hemodyna-
mics induced by CM. Thirty-nine patients who received 100 ml of a
non-ionic low osmolar CM (iopromide) were studied for changes in
GFR and RPF by continuous inulin and PAH clearance before and until
four hours after CM application. Forty-five minutes before the applica-
tion of CM, patients were randomized and received either theophylline
(5 mg/kg body wt) or the vehicle and placebo (saline) intravenously in a
blinded manner. We additionally measured the creatinine clearance on
the day before and two days after CM application. Sodium excretion,
N-acetyl-/3-glucosaminidase (NAG) excretion, plasma renin activity
(PRA) and aldosterone levels were also measured before and after CM
application. Theophylline levels were within the therapeutic range in
patients of the theophylline group during and four hours after CM
application (59.0 10.6 mol/liter and 40.1 10.9 tmol/liter). GFR,
measured by inulin clearance significantly declined under CM applica-
tion in patients without TP application (N = 19; 88 40 to 75 32
ml/min/l .72 m2; P <0.01). In the group of patients receiving theophyl-
line (N = 18) the GFR remained constant (75 26 vs. 78 33
mI/mm/I .72 m2). The same was true for the creatinine clearance
measured the day before and two days after CM application (89 41 vs.
66 32 mI/mm/I .72 m2 in the placebo group, P < 0.01, and 72 29 vs.
67 31 ml/minll .72 m2 in the theophylline group). In patients with renal
impairment (GFR <75 mI/mm) GFR, measured by inulin clearance also
declined significantly under CM application (55 20 ml/min/l .72 m2 vs.
47 22 mllmin/1.72 m2; P <0.05; N = 8) and remains constant in case
of theophylline application (54 16 ml/min/l .72 m2 vs. 57 23
ml/min/1.72 m2; N = 9). The creatinine clearance measured the day
before and two days after CM application showed the same tendency
without reaching statistical significance (39 21 mllmin/l .72 m2 vs. 29
22 mI/min/! .72 m2 in patients without theophylline, N = 5, and 46
14 ml/minll.72 m2 vs. 45 21 mllmin/1.72 m2, N = 6, in the
theophyllmne group). Regarding RPF measured by PAH clearance
before and until four hours after CM application, we could not detect
any significant changes. Sodium excretion and NAG excretion mea-
sured the day before and one day after CM application showed no
statistical significant changes either under CM application alone nor
under theophylline. PRA and aldosterone levels rose under theophyl-
line application (PRA: 1.8 2.4 vs. 5.6 6 ng/ml/hr, P < 0.05;
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aldosterone 109 135 pg/ml vs. 205 336 pg/mI). We conclude that
CM-induced reduction of GFR in patients with and without renal
function impairment can be prevented by infusion of theophylline. This
indicates that adenosine might play a major role in CM-associated ARF.
Despite the development of low-osmolality X-ray contrast
media (CM) renal failure induced by these agents has remained
an important clinical problem. Especially in patients with
existing renal failure, CM-induced nephropathy may be irre-
versible [1—3]. A slight decline in glomerular filtration rate
(GFR) has been detected in nearly all patients receiving CM,
when accurate and sensitive methods have been employed [4,
5].
The pathogenesis of CM-induced nephropathy is incom-
pletely understood. In general, it is believed that CM have
special effects on renal hemodynamics and may also exert some
tubular effects. In the non-renal circulation CM induce acute
vasoconstriction followed by prolonged vasodilation [4, 6].
However, the initial effect of CM on the renal circulation is
acute vasodilation with subsequent progressive vasoconstric-
tion [6—10]. This accompanies an increase in renal vascular
resistance and a concomitant decrease in both renal blood flow
(RBF) and glomerular filtration rate (GFR). Hence, some inves-
tigators believe that CM-induced nephropathy may serve as a
model of ischemic acute renal failure.
Based on animal experiments adenosine has been suggested
as a possible candidate for mediating renal vasoconstriction
after CM administration [11]. This postulate is derived from the
observation that adenosine can induce afferent arteriolar vaso-
constriction and a fall in GFR after intrarenal injection and
infusion in rats and dogs [12—17]. Since theophylline can inhibit
renal action of adenosine [12] by a competitive antagonism this
substance and more potent xanthine-derivates were used in
several animal studies to improve renal function after experi-
mental acute renal failure induced by ischemia [18—20], glycerol
administration [21—23] and contrast media injection [11].
According to the above mentioned findings we performed a
prospective, randomized and double-blind study to determine
whether theophylline as an adenosine antagonist can inhibit
CM-induced nephropathy in a clinical setting.
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Fig. 1. Study design.
Methods
Patients
The study protocol was approved by the Institutional Ethical
Committee. Thirty-nine Caucasian patients (11 females, 28
males) were prospectively enrolled in this study. Mean age was
55 13 years. All subjects gave prior written informed consent.
Patients could be recruited if they were supposed to receive at
least 100 ml of a low-osmolality CM (iopromide) in order to
undergo a radiologic investigation (computed tomography or
digital subtraction angiography). All patients were without a
history of allergic reactions to CM or theophylline. Pregnancy,
uncontrolled hypertension, and severe heart failure were exclu-
sion criteria. All drugs which might influence renal hemody-
namics including antihypertensive drugs and non-steroidal an-
tiinflammatory drugs were discontinued three days before the
study began.
Study protocol
All patients were studied on an in-patient basis. Patients were
randomized to receive either theophylline (5 mg/kg body wt,
Solosin®, Cassella-Riedel, Frankfurt, Germany) or the vehicle
with placebo (saline) intravenously. Theophylline or placebo
were given double-blindly 45 minutes before CM application. A
creatinine clearance was obtained the day before and the day
after CM application (Fig. 1). Patients were required to collect
urine for 24 hours. The serum values for determination of
creatinine, routine laboratory values, and hormones (renin and
aldosterone) were taken in the morning before breakfast the day
before CM application and until two days after. Blood pressure
measurements were obtained daily. Additionally, GFR (inulin
clearance) and RPF (PAH clearance) were determined with the
patients in supine position on the day of CM application,
beginning four hours before CM application and ending four
hours afterwards (Fig. 1).
Reasons for renal insufficiency in the study population were
diabetic nephropathy (N = 7), hypertensive renal damage (N =
2) and severe arteriosclerosis (N = 8).
Methods
Blood pressure was measured with a standard mercury
sphygmomanometer. Triple measurements were performed af-
ter 10 minutes of rest in supine position. GFR and RPF were
measured by means of a constant infusion technique of inulin
and PAH (para-aminohippurate) after an initial loading dose
starting at four hours before CM application. Inulin clearance
(C1) and PAH clearance (CpAH) parameters were calculated as
urine concentration divided by plasma concentration, multi-
plied by urine volume in mllmin, and were corrected for
standard body surface area (1.73 m2). During inulin and PAH
clearance periods patients received a water load of 1 liter/hr
with a sodium content of 0.43 g per liter in order to maintain
diuresis. Urine was collected by spontanous voiding. Serum
and urinary potassium, sodium, calcium, creatinine, uric acid
and albumin were measured by routine laboratory methods.
The peripheral venous hematocrit was determined via microhe-
matocrit technique. Plasma renin activity (PRA) and aldoste-
rone concentration were measured by radioimmunoassays (re-
nm: Serono Diagnostics; aldosterone: Diagnostic Products
Corp.).
All data are expressed as mean standard deviation (SD).
The Wilcoxon test was used to compare values of renal hemo-
dynamics, renin values, theophylline values and plasma renin
activity.
Results
From the 39 patients 19 received theophylline prior to CM
application and 20 received placebo. The characteristics of both
groups are shown in Table 1. There were no statistically
significant differences between the two groups. Renal hemody-
namics could be calculated only in 18 patients of the theophyl-
line group and in 19 patients of the placebo group due to
inadequate samples and misregistrations. The creatinine clear-
ance the day before and after CM application could only be
assessed in 13 patients of the placebo group and in 17 patients
of the theophylline group.
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Table 1. Patient characteristics
Theophylline
group(N = 19)
Placebo
group(N = 20)
Total
(N = 39)
Male 15/19 (79%) 13/20 (65%) 28/39 (72%)
Female 4/19 (21%) 7/20 (35%) 11/39 (28%)
Age years 59 10 52 14 55 13
Weight kg 74 11 69 10 71 10
Height cm 169 8 168 7 169 7
Creatinine mg/dl 1.2 0.5 1.2 0.9 1.2 0.7
Diabetics 3/19 (15%) 4/20 (15%) 7/39 (17%)
Patients with GFR 9/19 (47%) 8/20 (40%) 17/39 (43%)
<75 mI/mm/i .72 m2
No significant changes of routine laboratory values (Table 2)
were evident after CM application. PRA increased significantly
in the theophylline group (1.8 2.4 vs. 5.6 6 ng/ml/hr)
measured second days after theophylline administration (P <
0.05; Table 2). The rise in aldosterone after CM application in
the theophylline group did not reach statistical significance due
to a large variance (Table 2).
Changes in renal hemodynamics measured by inulin and PAH
clearance before and during four hours after CM application are
shown in Table 3. The inulin clearance decreased in the placebo
group (88 40 vs. 75 20 ml/min/l.72 m2; P < 0.01). Patients
with a GFR below 75 mI/mm (values in parentheses Table 3 and
hatched lines in Fig. 2) also respond to CM with a decrease in
GFR (55 22 vs. 47 22 mllminll.72 m2; P <0.05). PAH
clearance did not change significantly (Table 3, Fig. 3). The
additionally measured creatinine clearance two days after CM
application revealed the same results as the inulin clearance on
the day of CM application, that is, a significant decrease in the
placebo group (P < 0.01) and no changes in the theophylline
group (Table 3, Fig. 4). When looking only at patients with renal
insufficiency (creatinine clearance below 75 mllmin) the de-
crease in GFR under placebo did not reach significance, due to
the low number of patients (values in parentheses Table 3,
hatched line in Fig. 4).
No significant differences of the excretion of sodium and
n-acetyl-/3-glucosaminidase (NAG) measured before and at
least four hours after CM application were found. The slight
increase in sodium excretion in both groups may be attributed
to volume load induced by oral hydration during the inulin and
PAH clearance measurements.
Discussion
CM induced nephropathy can be defined as otherwise unex-
plained acute renal function deterioration after intravascular
administration of iodinated CM. The incidence of this condition
ranges in the literature from less than 1% to over 70% [24—27].
So far the application of new and more expensive X-ray CM
with lower osmolality failed to demonstrate unequivocal supe-
riority in terms of renal injury [27—3 1].
The pathogenesis of CM induced nephropathy is incom-
pletely understood. In general, it is believed that CM have
special effects on renal hemodynamics and may also exert some
tubular effects. In our patients marked changes in renal hemo-
dynamics were demonstrated (Table 3) but there were no
statistical significant changes in NAG excretion. This may be
due to the time of measurement, as NAG is said to be an early
marker of tubular damage after CM application and increases
about fivefold shortly after CM application [32, 33].
In animal studies an abrupt increase followed by a decrease in
RBF after CM application is believed to be the major factor of
GFR decline [4, 6—10, 34]. Studies in humans have also shown
a decrease in PAH extraction and PAH clearance lasting
between two and 60 minutes after CM application and is
followed by a decrease in GFR with a maximum increase in
creatinine one to three days after CM application [2, 27, 32,
35—39]. RPF measured by PAH clearance showed no significant
changes four hours after CM application in the present study.
This may be attributed to the time schedule of the RPF
measurement, because others could not demonstrate changes of
RPF at this late time after CM application, too [37, 40]. It must
also be considered that PAH clearance measurements in the
presence of CM are known to overestimate RPF because CM
impede PAH excretion especially in patients with renal function
impairment [35, 41, 42]. Studies using other RPF and RBF
measurement techniques in humans are contradictory [36, 37,
43]. Even renal vasodilation after an initial vasoconstnction
lasting only very shortly after CM application has been reported
[37].
CM administration in our study resulted in a significant
decline of 15% and 23% in GFR, measured either by inulin
clearance until four hours after CM application or by creatinine
clearance measured two days after CM application, respec-
tively. As an underlying renal insufficiency seems to be an
important predisposing factor for CM nephrotoxicity [2—5, 28,
44—46] the GFR of patients with a GFR below 75 mi/mm was
calculated, also (Table 3, Figs. 2 and 3). However, no difference
between patients with normal GFR and renal function impair-
ment regarding changes in inulin clearance after CM application
was demonstrable in our patients. The decrease in GFR mea-
sured by creatinine clearance two days after CM application did
not reach statistical significance in the placebo group. This may
be due to the low number of patients (N = 5). Intravenous
administration of theophylline (5 mg/kg body wt) 45 minutes
before CM application prevented the decline of GFR in patients
with and without renal function impairment (Table 3, Figs. 2
and 3). These findings compare well with the study done in
animals concerning the fact of prevention of GFR decline after
theophylline administration [11]. The observation that the cre-
atinine clearance appeared to be consistently lower than the
inulin clearance, especially in patients with kidney disease, may
be explained by differences in the hydration status because
patients were water loaded at the time of the inulin clearance.
Time differences may have played a role, too, as the creatinine
clearance was obtained by collecting the urine over a period of
24 hours.
Theophylline is well known as a specific adenosine antagonist
and it has been used widely in animal models to prevent acute
renal failure, induced by clipping the renal artery [18—20] or
injection of nephrotoxic agents [11, 18, 21—23]. These favorable
effects of theophylline in maintaining the GFR are believed to
be due to its role as a specific adenosine antagonist [11, 12].
Theophylline concentrations in the millimolar range exhibit an
inhibitory effect on the phosphodiesterase [12]. However,
plasma concentrations above 0.1 mmol/liter are toxic [12]. In
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Table 2. Routine laboratory parameters measured before and four hours after CM application
Theophylline group Placebo group
Blood pressure before CM mm Hg 137 18/81 9 (N = 18) 127 18/77 12 (N = 19)
Blood pressure after CM mm Hg 141 23/82 12 (N = 17) 133 22/77 11 (N = 17)
Heart rate before CM beats/mm 69 10 (N = 17) 69 6 (N = 19)
Heart rate after CM beats/mm 74 11 (N = 17) 68 6 (N = 17)
Serum sodium before CM mmoi/liter 140 3 (N = 18) 139 3 (N = 19)
Serum sodium after CM mmoi/liter 135 3 (N = 18) 138 3 (N = 18)
Creatinine before CM mg/d! 1 .2 0.5 (N = 18) 1.2 0.9 (N = 19)
Creatine after CM mg/dl 1.0 0.4 (N = 18) 1.1 0.7 (N 18)
PRA before CM ng/mi/hr 1.8 2.4 (N 19) 1.4 1.7 (N = 19)
PRA 2 days after CM ng/m!/hr 5.6 6 (N = l3) 2.3 2.3 (N = 16)
Aldosterone before CM pg/mi 109 135 (N = 19) 106 151 (N = 19)
Aldosterone 2 days after CM pg/mi 205 336 (N = 13) 128 84 (N 16)
Theophylline before CM pinol/liter
Theophylline 30 mm after CM munoi/!iter
Theophylline 1 hour after CM pno1/iiter
1.2 3.6 (N = 18)
59.0 10.6 (N = 17)'
40.1 10.9 (N = l8)'
0.7 3.0 (N 19)
1.2 3.7 (N = 19)
0.6 2.4 (N = 19)
Values for PRA and aldosterone concentration were determined in the morning on the day of CM application and two days thereafter.
ap < 0.05 compared to the values before CM applicationbP < 0.01 compared to the values before CM application
Table 3. Renal hemodynamics after CM application
Theophylline
group Placebo group
A Placebo
200
72 29 (N = 13)
[46 14 (N = 6)]
67 31 (N = 13)
[45 21 (N = 6)]
75 26 (N = 18)
[54 16 (N = 9)]
78 33 (N = 18)
[57 23 (N = 9)]
354 189 (N 18)
Creatinine clearance day
before CM
mi/min/1.72 m2
Creatinine clearance 2
days after CM mi/min/
1.72 m2
Inulin clearance before
CM mI/mm/i .72 m2
Inulin clearance after CM
ml/min/1.72 m2
PAH clearance before
CM ml/min/J.72 m2
PAH clearance after CM 351 167 (N = 18) 417 150 (N = 19)
mi/min/1.72 n2
89 41 (N = 17)
[39 21 (N = 5)]
66 32 (N = 17)b
[29 22 (N = 15)]
88 40 (N = 19)
[55 20 (N = 8)]
75 32 (N =
[47 22 (N = 8)]
457 192 (N = 19)
150
E
1000C
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(.)
C
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0
Before CM After CM
B Theophylline200
150
100
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E
a)0C
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Inulin and PAH clearances (ml/minll .72 m2) were measured one hour
before and until four hours after CM application (Fig. 1); creatinine
clearance was measured the day before CM application and two days
after CM application. Values in parenthesis revealed values of patients
with renal impairment.
a P < 0.05
l, P < 0.01, when comparing values before and after CM administra-
tion
the micromolar range theophylline acts primarily as a compet-
itive antagonist of adenosine by replacing adenosine from its
binding onto membrane fragments. The therapeutic actions of
theophylline in the dose we used (40 to 59 mo1Iliter) are most
probably attributable to an antagonism of adenosine [12]. It has
been postulated that adenosine is involved in the control of
renal hemodynamics [17, 47]. Short periods of ischemia lead to
a severalfold increase in adenosine tissue levels within the rat
kidney [48], which is also true for humans (Osswald, Kemper,
unpublished data). Adenosine administered into the renal artery
lead to a vasoconstriction and a marked decrease in SNGFR of
superficial glomeruli and also a fall in whole kidney GFR [13,
15, 16]. It has also been demonstrated that changes in renal
hemodynamics induced by adenosine are pronounced when the
renin-angiotensin-aldosterone system is activated [14]. This
applies also to patients scheduled for CM application [4, 49].
75 mI/mm - NSNS
0
Before CM After CM
Fig. 2. Inulin clearance before and after contrast media (CM) appli-
cation. Each line represents one patient. The heavy line represents
mean values for all patients, hatched line represents mean values for
patients with GFR < 75 ml/min. Abbreviation is NS, not significant.
Our finding of an increase in PRA only in the group receiving
theophylline can also be explained by its adenosine antagonism,
because adenosine induced a decrease of renin secretion [14].
The sodium status of the patients in our study was kept high
B Theophylline
NS
Before CM After CM
Fig. 3. PAH clearance before and after contrast media (CM) applica-
tion. Each line represents one patient. The heavy line represents mean
values for all patients.
(see Tables 2 and 4), according to the observation that sodium
depletion accentuates both the magnitude and the duration of
the vasoconstrictive phase of the renal blood flow response to
injection of contrast media [49]. On the other hand it has been
shown that angiotensin II receptor blockers and converting
enzyme inhibition provided only incomplete protection against
CM induced nephropathy [49]. This indicates that the renin-
angiotensin system does not play a major role in mediating
contrast-induced changes.
In summary, we could demonstrate a GFR decline measured
by inulin clearance until four hours after CM application and
also two days after CM application measured by creatinine
clearance which could be prevented by theophylline applica-
tion. To our knowledge, there is only one previous communi-
cation in the literature dealing with this point [50]. The authors
studied creatinine clearances measured before and three days
after CM application in 21 patients undergoing coronary angiog-
raphy. They did not find a beneficial effect of 125 mg ( 1.5
mg/kg) theophylline given before and until 48 hours after CM
application. However, the small number of patients limits the
conclusions which can be drawn from the study. In addition,
the low dose of theophylline used might not have yielded serum
levels in the therapeutic range.
In conclusion, our study results indicate a major role for
75 mI/mm Ti-NSNS
Theophylline group Placebo group
Sodium excretion 0.97 0.46 (N = 18) 1.01 0.53 (N = 19)
before CM
mmollmin
Sodium excretion 1.06 0.39 (N = 17) 1.45 0.93 (N = 19)
after CM
mmol/min
NAG secretion 6.2 9.3 (N = 17) 5.8 9.9 (N = 18)
before CM
mU/mm
NAG excretion 6.7 6.5 (N = 18) 4.8 4.6 (N = 17)
after CM
mU/mm
adenosine in CM-induced nephropathy. Adenosine antagonism
can prevent renal function decline in patients with and without
renal failure. The use of adenosine antagonists may be benefi-
cial in patients with pre-existing renal function impairment.
Further studies have to clarify the clinical significance of this
observation in a larger number of patients, and in patients with
diabetic nephropathy, since these patients run the highest risk
for nephrotoxic renal failure. As adenosine may play a role in
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Fig. 4. Creatinine clearance before and after contrast media (CM)
application. Each line represents one patient. The heavy line represents
mean values for all patients, hatched line represents mean values for
patients with GFR < 75 mI/mm. Abbreviation is NS, not significant.
Table 4. Urine values measured one day before and one day after
CM application
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acute renal failure regardless of the underlying damage [11,
18—23] the renal protective properties of theophylline and other
adenosine antagonists should also be evaluated in situations of
nephrotoxic damage unrelated to the administration of iodi-
nated contrast media. These situations might include the use of
cyclosporin A, gentamycin or amphotericin B.
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